GlassScriptPhysician profile
Andrew Parker
NPI 1902168107
$6,393.86
in general payments reported to CMS, 2019-2025
20 companies · $1,046 in 2025
The $1,046 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $4,607 · 2021: $82.15 · 2022: $44.78 · 2024: $61.38 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,107.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $4,594.31 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $388.31 | 2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $229.26 | 2019-2021 | |
| Optinose US, INC. | $192.00 | 2019-2021 | |
| Genzyme Corporation | $166.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $147.37 | 2025 | Tezspire, Fasenra, Airsupra |
| Biocryst US Sales Co., LLC | $140.09 | 2024-2025 | Orladeyo |
| Circassia INC. | $114.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $82.54 | 2025 | |
| Csl Behring | $77.17 | 2019-2021 | |
| Pharming Healthcare, INC. | $56.76 | 2022-2025 | Ruconest |
| Incyte Corporation | $29.95 | 2025 | Opzelura |
| Kaleo, INC. | $28.86 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $28.38 | 2025 | Dawnzera |
| Takeda Pharmaceuticals U.S.A., INC. | $24.42 | 2025 | Takhzyro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $24.17 | 2025 | Neffy |
| Invivyd INC | $21.65 | 2025 | Pemgarda |
| Genentech USA, INC. | $19.02 | 2025 | Xolair |
| Glaxosmithkline, LLC. | $14.30 | 2025 | Nucala |
| Amgen INC. | $14.27 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.